Kynos Therapeutics

Cancer research
#Acute inflammatory conditions #Clinical trial #KMO inhibitor #Kynos Therapeutics #Phase I trial #University of Edinburgh

Positive Phase I results for KMO inhibitor in inflammatory disorders

Kynos Therapeutics has announced positive top line results from the first in human Phase I trial of its lead drug candidate, KMO inhibitor KNS366, for acute and chronic inflammatory disorders. KMO is an enzyme that acts at a key point in the kynurenine pathway of… Read More

#News

Medical research
#Drug discovery #Kynos Therapeutics #Phase I trial

First-in-human Phase I study of KMO inhibitor launches in UK

Scotland-based Kynos Therapeutics has launched a first-in-human Phase I trial of its kynurenine 3-monooxygenase (KMO) inhibitor KNS366. The study aims to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of KNS366 in healthy adult participants. The study is being conducted at a… Read More

#News